Freedom to Operate

The increase in R&D costs and the risks of costly patent infringement litigation and subsequent damages claims require companies to ensure that they develop and maintain cost-effective Freedom to Operate (FTO) strategies.

The 2013 Forum will focus on all aspects of FTO, including a timeline with best practices at significant milestones in the development of a drug, details of the latest developments and their ramifications for FTO searches, how to conduct more time and cost efficient FTO searches and analysis, guidance on the interpretation of the results and quantification of the risks and the formulation of a suitable FTO strategy.

Once again, C5’s leading event will gather together leading experts in the industry who will provide vital insights into the most effective ways to analyse and interpret the existing patent landscape, tips on how to overcome cross-jurisdictional challenges and updates on the latest regulatory and case-law developments, in addition to emerging trends which impact upon your FTO processes.  In addition, regional experts will provide tips and techniques for surmounting obstacles commonly encountered in emerging markets, including China, India and Brazil.  Find out how to conduct the most comprehensive FTO search in the most time efficient manner.

C5’s 10th Freedom to Operate Forum brings together eminent in-house counsel from the world’s largest pharma, biotech and chemical companies and their expert advisors from a range of jurisdictions including the US, Europe and Asia. Based on their first-hand experience, the distinguished panel will provide you with invaluable information and insights on FTO with a particular focus on developments in:

• Best practices for a good FTO search strategy
• Strategies for more time- and cost-effective FTO searches
• Interpreting FTO search results and challenging validity to overcome blocking patents
• How EPO divisional applications are impacting FTO strategies
• Latest updates on important patent court decisions and their implications for your FTO strategy: Lilly v HGS and Brustle v Greenpeace
• Maximising the FTO benefits of patent extensions: SPCs, Regulatory Data and paediatric extensions
• Finding the right balance when reporting your FTO strategy: privilege and confidentiality
• Quantifying FTO Risks
• FTO in emerging markets with a focus on China, India and Brazil
• The impact of US Patent Reform on European FTO analysis

Plus, add practical value to your experience when you attend the programme’s workshop on:
Reading and Analysing Claims in Patents and Patent Applications

For more information, please contact:

Speaking opportunities:
Ben Sharples
Tel: : +44 (0) 20 7878 6980
b.sharples@c5-online.com

Marketing and media support enquiries:
Karina Kusova, C5
Tel: +44 (0) 20 7878 6956
k.kusova@c5-online.com

Business development opportunities:
Brian Reffell, C5
Tel: +44 (0) 20 7878 6933
b.reffell@c5-online.com

Sponsors:

Media Partners:

- Actions -

- Share -